Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.

Bédard AC, Stein MA, Halperin JM, Krone B, Rajwan E, Newcorn JH.

J Child Psychol Psychiatry. 2014 Jun 19. doi: 10.1111/jcpp.12272. [Epub ahead of print]

PMID:
24942409
[PubMed - as supplied by publisher]
2.

Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.

Kratz O, Studer P, Baack J, Malcherek S, Erbe K, Moll GH, Heinrich H.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):81-9. doi: 10.1016/j.pnpbp.2011.12.008. Epub 2011 Dec 29.

PMID:
22227291
[PubMed - indexed for MEDLINE]
3.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

PMID:
17874862
[PubMed - indexed for MEDLINE]
Free Article
4.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

PMID:
16796929
[PubMed - indexed for MEDLINE]
Free Article
5.

Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):121-31. doi: 10.1089/cap.2010.0047. Epub 2011 Apr 13.

PMID:
21488750
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.

Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, Macdonald M, Lohman M, Bailey GL, Haynes L, Jaffee WB, Haminton N, Hodgkins C, Whitmore E, Trello-Rishel K, Tamm L, Acosta MC, Royer-Malvestuto C, Subramaniam G, Fishman M, Holmes BW, Kaye ME, Vargo MA, Woody GE, Nunes EV, Liu D.

J Am Acad Child Adolesc Psychiatry. 2011 Sep;50(9):903-14. doi: 10.1016/j.jaac.2011.06.010. Epub 2011 Aug 4.

PMID:
21871372
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

PMID:
23801529
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder.

Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):663-71. doi: 10.1089/cap.2009.0033.

PMID:
20035584
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.

Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T.

J Clin Psychopharmacol. 2012 Oct;32(5):653-60.

PMID:
22926599
[PubMed - indexed for MEDLINE]
10.

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS.

Adv Ther. 2005 Sep-Oct;22(5):498-512.

PMID:
16418159
[PubMed - indexed for MEDLINE]
11.

OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.

Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.

Eur Neuropsychopharmacol. 2014 Apr;24(4):519-28. doi: 10.1016/j.euroneuro.2014.01.007. Epub 2014 Jan 18.

PMID:
24508533
[PubMed - in process]
12.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
[PubMed - indexed for MEDLINE]
13.

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.

PMID:
21488751
[PubMed - indexed for MEDLINE]
14.

Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.

Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y.

Int J Neuropsychopharmacol. 2012 Feb;15(1):15-26. doi: 10.1017/S1461145711001490. Epub 2011 Oct 21.

PMID:
22017969
[PubMed - in process]
15.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.

Depress Anxiety. 2009;26(3):212-21. doi: 10.1002/da.20549.

PMID:
19194995
[PubMed - indexed for MEDLINE]
16.

Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder.

Lee SH, Song DH, Kim BN, Joung YS, Ha EH, Cheon KA, Shin YJ, Yoo HJ, Shin DW.

Yonsei Med J. 2009 Oct 31;50(5):650-5. doi: 10.3349/ymj.2009.50.5.650. Epub 2009 Oct 21.

PMID:
19881968
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
[PubMed - indexed for MEDLINE]
18.

Dissociation in response to methylphenidate on response variability in a group of medication naïve children with ADHD.

Johnson KA, Barry E, Bellgrove MA, Cox M, Kelly SP, Dáibhis A, Daly M, Keavey M, Watchorn A, Fitzgerald M, McNicholas F, Kirley A, Robertson IH, Gill M.

Neuropsychologia. 2008 Apr;46(5):1532-41. doi: 10.1016/j.neuropsychologia.2008.01.002. Epub 2008 Jan 12.

PMID:
18289615
[PubMed - indexed for MEDLINE]
19.

Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status.

Huang YS, Wang LJ, Chen CK.

BMC Psychiatry. 2012 Nov 9;12:194. doi: 10.1186/1471-244X-12-194.

PMID:
23140464
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.

Pediatrics. 2001 Oct;108(4):883-92.

PMID:
11581440
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk